PX1 Research provides laboratory institutions with analytical-grade Bronchogen synthesized specifically for in vitro and preclinical investigation. As a premier USA-based supplier, PX1 ensures every lot undergoes rigorous HPLC and mass spectrometry testing to meet strict purity requirements for mucosal barrier and respiratory epithelium research.
PX1 Research provides laboratory institutions with analytical-grade Bronchogen synthesized specifically for in vitro and preclinical investigation. As a premier USA-based supplier, PX1 ensures every lot undergoes rigorous HPLC and mass spectrometry testing to meet strict purity requirements for mucosal barrier and respiratory epithelium research.
A reliable bronchogen mucosal edema supplier provides laboratory researchers with highly purified, synthetically verified Ala-Glu-Asp-Leu tetrapeptide designed exclusively for controlled preclinical models. PX1 Research supplies USA-manufactured, endotoxin-tested Bronchogen featuring lot-specific third-party certificates of analysis (COA), high-performance liquid chromatography (HPLC) traces, and mass spectrometry data to guarantee quantitative reproducibility in mucosal membrane and respiratory tissue experiments.
Evaluating supplier integrity requires evaluating not only raw purity percentages, but also batch-to-batch consistency, moisture content, and heavy metal limits. Researchers establishing cell culture assays or animal models of epithelial permeability rely on PX1 Research for non-clinical peptides free from residual trifluoroacetic acid (TFA) salts or bacterial contaminants that could skew biological assays.
Bronchogen is a synthetic short bioregulatory tetrapeptide comprising the amino acid sequence L-alanyl-L-glutamyl-L-aspartyl-L-leucine (Ala-Glu-Asp-Leu). Designed to mimic key peptide fragments derived from bronchopulmonary chromatin proteins, it interacts directly with genomic structures and cellular transcription machinery in respiratory epithelial cells.
In cell-free and cellular in vitro research, Bronchogen demonstrates a capacity to modulate gene expression related to cellular differentiation, mucociliary clearance, and structural protein synthesis. The peptide's low molecular weight allows for efficient cellular uptake in cultured bronchial epithelial cells, making it an ideal candidate for dissecting signal transduction pathways under hyper-inflammatory or oxidative conditions.
Understanding the primary sequence and physicochemical properties of Bronchogen is critical when selecting reagents for specific laboratory assays. As a hydrophilic peptide with carboxyl-rich side chains, its solubility and conformational stability in aqueous buffers heavily depend on ambient pH, ionic strength, and precise temperature regulation during preparation.
Mucosal edema is a hallmark of acute inflammatory responses in pulmonary tissue, characterized by the breakdown of tight junctions, fluid accumulation in the interstitial space, and impaired barrier function. Preclinical models investigating mucosal edema frequently utilize Bronchogen to observe its protective and restorative effects on bronchial epithelial monolayers.
In vitro data indicate that Bronchogen application to inflamed respiratory cell lines helps maintain transepithelial electrical resistance (TEER) by stabilizing key tight junction proteins such as ZO-1 and occludin. Furthermore, rodent models of lipopolysaccharide (LPS)-induced acute lung injury show that administration of research-grade Bronchogen correlates with reduced vascular permeability, lower wet-to-dry lung weight ratios, and suppressed pro-inflammatory cytokine expression (including TNF-alpha and IL-6).
Laboratory studies also highlight Bronchogen's potential role in regulating surfactant protein production and suppressing excessive fibroblast proliferation during the recovery phase of pulmonary edema. By attenuating the hyper-inflammatory cascade, the compound enables researchers to evaluate tissue-remodeling mechanisms without inducing unspecific cellular toxicity.
When designing protocols for pulmonary inflammation, tissue remodeling, or mucosal breakdown, principal investigators often compare Bronchogen against other synthetic bioregulatory and cytoprotective peptides. Selecting the appropriate compound depends on whether the primary target is epithelial integrity, systemic immune modulation, or cellular repair pathways.
For instance, researchers comparing respiratory bioregulators often evaluate Chonluten alongside Bronchogen, as both short-chain peptides target bronchopulmonary tissue, though Chonluten primarily influences macrophage activation and cytokine signaling. Similarly, studies examining broader mucosal recovery often incorporate Thymogen for T-cell mediated immune modulation, or BPC-157 for general cytoprotective and angiogenic signaling across various epithelial tissues. Combining these reagents in controlled comparative assays helps map distinct overlapping pathways in cellular stress models.
Below is an overview comparing Bronchogen to other common peptide reagents used in epithelial and tissue repair research:
Research outcomes depend entirely on reagent purity and identity. When sourcing compounds for complex assays, partnering with a specialized bronchogen mucosal edema supplier ensures that the material is verified through rigorous analytical methods rather than simple spot-checking.
PX1 Research implements a strict quality assurance protocol for every peptide batch. Our process includes:
1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Ensures chemical purity exceeds 98%, identifying and quantifying minor synthesis byproducts.
2. Electrospray Ionization Mass Spectrometry (ESI-MS): Confirms exact molecular mass (Ala-Glu-Asp-Leu) to verify correct sequence identity.
3. Endotoxin Quantitation (LAL Assay): Verifies endotoxin levels remain below 0.1 EU/mg, preventing false-positive inflammatory responses in cell culture models.
4. Amino Acid Analysis (AAA): Confirms stoichiometric accuracy of the peptide sequence and quantifies net peptide content vs. counter-ion salts.
Proper reconstitution techniques are vital to preserve peptide integrity and achieve reproducible concentrations in biological assays. Bronchogen is supplied as a lyophilized (freeze-dried) powder packaged under an inert argon atmosphere to protect against moisture absorption and oxidation.
For lab-scale reconstitution, researchers should allow the vial to equilibrate to room temperature before opening to prevent condensation inside the container. Dissolve the lyophilized powder using sterile, deionized water or phosphate-buffered saline (PBS, pH 7.4). For long-term stability in liquid media, stock solutions should be aliquoted into single-use polypropylene microtubes to avoid repeated freeze-thaw cycles.
Avoid high-energy sonication or vigorous vortexing, which can introduce mechanical shear stress and induce aggregation. Gentle inversion or mild swirling is recommended to achieve complete dissolution. If low-concentration working solutions are required, dilute immediately prior to application in culture media or assay buffers.
Lyophilized Bronchogen should be stored at -20°C for short-to-medium term storage (up to 12 months) or at -80°C for extended archival preservation. Desiccant packs should be kept in the storage container to protect the cake from ambient humidity.
Reconstituted stock solutions remain stable at 2°C to 8°C for up to 7 days, provided sterile handling procedures are maintained. For prolonged experiments, stock solutions held at -20°C or -80°C remain viable for up to 3 to 6 months. Researchers should consult the lot-specific Certificate of Analysis provided with their shipment from PX1 Research for precise stability data and recommended re-test dates.
PX1 Research operates as a dedicated USA-based vendor committed strictly to supporting scientific advancement. We manufacture our compounds in GMP-compliant facilities and utilize independent ISO 17025 accredited laboratories to perform third-party testing on every production lot.
Institutions sourcing through our wholesale lab portal or standard catalog benefit from fast, reliable fulfillment with same-day shipping on orders placed Monday through Friday. Every vial is shipped from our secure distribution facilities in California and Arizona, complete with full lot traceability and direct access to comprehensive analytical documentation.
Explore our complete catalog of all research peptides to support your institution's cell biology, histology, and molecular pharmacology experiments.
What is Bronchogen used for in laboratory research?
Bronchogen (Ala-Glu-Asp-Leu) is studied in preclinical and in vitro models to investigate respiratory epithelial cell dynamics, mucosal barrier integrity, tight junction regulation, and inflammatory signaling pathways involved in pulmonary tissue remodeling.
How does PX1 Research verify Bronchogen purity?
PX1 Research verifies every lot of Bronchogen using RP-HPLC for chemical purity (>98%) and ESI-MS for exact molecular weight confirmation. Endotoxin testing via LAL assay ensures levels are below 0.1 EU/mg.
What is the recommended reconstitution solvent for Bronchogen?
Bronchogen is readily soluble in sterile water for injection or sterile phosphate-buffered saline (PBS, pH 7.4). Solubilization should be performed under sterile laminar flow conditions.
Can Bronchogen be used for human treatment or clinical administration?
No. Bronchogen supplied by PX1 Research is strictly designated for laboratory research use only (RUO). It is not intended for human or animal consumption, medical treatment, or clinical application.
How should reconstituted Bronchogen stock solutions be stored?
Reconstituted solution should be divided into single-use aliquots and stored at -20°C or -80°C to prevent degradation from repeated freeze-thaw cycles. Short-term storage at 2–8°C is acceptable for up to 7 days.
Where does PX1 Research ship Bronchogen from?
All PX1 Research products are manufactured in the USA and shipped directly from our warehouse facilities in California and Arizona, with same-day dispatch available Monday through Friday.
How does Bronchogen compare to Chonluten in respiratory models?
While both are short bioregulatory peptides targeting respiratory tissue, Bronchogen (Ala-Glu-Asp-Leu) primarily focuses on epithelial barrier stability and gene transcription in bronchial cells, whereas Chonluten targets macrophage response and systemic cytokine regulation.
Where can I find the Certificate of Analysis (COA) for my Bronchogen lot?
Every product shipped by PX1 Research includes a batch-specific COA. Researchers can also access public COA files or request lot verification directly through our customer portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.